Lonapegsomatropin is a pegylated prodrug of the human growth hormone, somatropin, administered as a subcutaneous injection once-weekly.

The Food and Drug Administration (FDA) has extended the review period for elinzanetant, an investigational hormone-free therapy for the treatment of moderate to severe vasomotor symptoms (VMS) due to ...

AOMs linked to significant weight regain at eight weeks after drug discontinuation compared with control group.

US Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. signed off on the recommendation from an expert panel that recommended removing the mercury-based preservative from all influenza ...

HealthDay News — Patients with irritable bowel syndrome (IBS) with self-perceived gluten sensitivity react similarly to wheat, gluten, and sham challenges, according to a study published online July ...

HealthDay News — Reusable feminine hygiene products often contain per- and polyfluoroalkyl substances (PFAS), according to a study published online July 22 in Environmental Science & Technology ...

Following publication of advisories, reports of local anesthetic poisoning decreased, but reports of lidocaine poisoning and mortality increased.

SAP-001 is an investigational oral agent designed to reduce serum uric acid levels by targeting a distinct renal urate reabsorption transporter.

The approval was based on data from the randomized, double-blind, placebo-controlled phase 3b AVA-PED-301 trial.

Elevidys shipments paused following third death; FDA committee votes against brexpiprazole combo for PTSD; Rapiblyk now available for SVT; sleep apnea pill looks promising; JUUL e-cigarettes gain ...

No difference in mortality risk seen for GLP-1 RA and SGLT2i users; significantly lower risk seen for GLP-1 RA vs DPP4i users.

The recall of more than 160,000 bottles of levothyroxine sodium, which went into effect June 20, was upgraded to a Class II recall on July 23. Class II recalls occur when use of the drug poses a ...